|By PR Newswire||
|August 27, 2014 07:11 AM EDT||
DALLAS, Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty Liver Disease Global Clinical Trials Review, H2, 2014″ provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fatty Liver Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fatty Liver Disease.
Fatty liver, also known as fatty liver disease (FLD), is a reversible condition wherein large vacuoles of triglyceride fat accumulate in liver cells via the process of steatosis (i.e., abnormal retention of lipids within a cell). Despite having multiple causes, fatty liver can be considered a single disease that occurs worldwide in those with excessive alcohol intake and the obese (with or without effects of insulin resistance). The condition is also associated with other diseases that influence fat metabolism. It is difficult to distinguish alcoholic FLD from nonalcoholic FLD, and both show microvesicular and macrovesicular fatty changes at different stages.
Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=9795 . (This is a premium report priced at US$2500 for a single user License.)
Clinical Trial Overview of Top Companies:
- Merck & Co., Inc.
- Galmed International Ltd.
- F. Hoffmann-La Roche Ltd.
- PharmaKing Co., Ltd.
- Abbott Laboratories
- TCM Biotech International Corp
- Phenex Pharmaceuticals AG
- GW Pharmaceuticals plc
- Genextra S.p.a
Clinical Trial Overview of Top Institutes / Government:
- The National Institute of Diabetes and Digestive and Kidney Diseases
- Tabriz University of Medical Sciences
- Third Military Medical University
- University of Michigan
- Tehran University of Medical Sciences
- Washington University School of Medicine
- University of California, San Diego
- FUDAN University
- Ahvaz Jundishapur University of Medical Sciences
- Bambino Gesu Hospital and Research Institute
Accumulation of fat may also be accompanied by a progressive inflammation of the liver (hepatitis), called steatohepatitis. By considering the contribution by alcohol, fatty liver may be termed alcoholic steatosis or nonalcoholic fatty liver disease (NAFLD), and the more severe forms as alcoholic steatohepatitis (part of alcoholic liver disease) and Non-alcoholic steatohepatitis (NASH).
The treatment of fatty liver depends on its cause, and, in general, treating the underlying cause will reverse the process of steatosis if implemented at an early stage. Two known causes of fatty liver disease are an excess consumption of alcohol and a prolonged diet containing foods with a high proportion of calories coming from lipids. For the patients with non-alcoholic fatty liver disease with pure steatosis and no evidence of inflammation, a gradual weight loss is often the only recommendation. In more serious cases, medications that decrease insulin resistance, hyperlipidemia, and those that induce weight loss have been shown to improve liver function
Complete Report Available @ http://www.marketoptimizer.org/fatty-liver-disease-global-clinical-trials-review-h2-2014.html .
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Fatty Liver Disease 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Fatty Liver Disease 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Fatty Liver Disease Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Fatty Liver Disease 33
Jul 30, 2014: Galectin Therapeutics Issues Statement on GR-MD-02 Development Program 33
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 34
Clinical Trial Profiles 35
Explore more reports on Pharmaceuticals industry at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals .
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Media Contact: Ritesh Tiwari, MarketOptimizer, +18883915441, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
Nov. 25, 2015 09:00 AM EST Reads: 261
Nov. 25, 2015 08:15 AM EST Reads: 341
Nov. 25, 2015 07:45 AM EST Reads: 339
Nov. 25, 2015 07:30 AM EST Reads: 246
Nov. 25, 2015 07:15 AM EST Reads: 153
Nov. 25, 2015 06:45 AM EST
Nov. 25, 2015 05:45 AM EST Reads: 375
Nov. 25, 2015 05:45 AM EST Reads: 287
Nov. 25, 2015 02:30 AM EST Reads: 680
Nov. 25, 2015 02:00 AM EST Reads: 287
Nov. 25, 2015 12:30 AM EST Reads: 410
Nov. 25, 2015 12:30 AM EST Reads: 416
With all the incredible momentum behind the Internet of Things (IoT) industry, it is easy to forget that not a single CEO wakes up and wonders if “my IoT is broken.” What they wonder is if they are making the right decisions to do all they can to increase revenue, decrease costs, and improve customer experience – effectively the same challenges they have always had in growing their business. The exciting thing about the IoT industry is now these decisions can be better, faster, and smarter. Now ...
Nov. 25, 2015 12:00 AM EST Reads: 162
PubNub has announced the release of BLOCKS, a set of customizable microservices that give developers a simple way to add code and deploy features for realtime apps.PubNub BLOCKS executes business logic directly on the data streaming through PubNub’s network without splitting it off to an intermediary server controlled by the customer. This revolutionary approach streamlines app development, reduces endpoint-to-endpoint latency, and allows apps to better leverage the enormous scalability of PubNu...
Nov. 24, 2015 10:00 PM EST Reads: 259
I recently attended and was a speaker at the 4th International Internet of @ThingsExpo at the Santa Clara Convention Center. I also had the opportunity to attend this event last year and I wrote a blog from that show talking about how the “Enterprise Impact of IoT” was a key theme of last year’s show. I was curious to see if the same theme would still resonate 365 days later and what, if any, changes I would see in the content presented.
Nov. 24, 2015 08:00 PM EST Reads: 342